# A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors

> **NCT07317505** · PHASE1 · RECRUITING · sponsor: **Conjupro Biotherapeutics, Inc.** · enrollment: 270 (estimated)

## Conditions studied

- Cancer
- Cancer (Solid Tumors)

## Interventions

- **DRUG:** JMT108

## Key facts

- **NCT ID:** NCT07317505
- **Lead sponsor:** Conjupro Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-02
- **Primary completion:** 2029-07
- **Final completion:** 2029-09
- **Target enrollment:** 270 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07317505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07317505, "A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07317505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*